Stay updated on Pembrolizumab + Gemcitabine in UC Subjects Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Gemcitabine in UC Subjects Clinical Trial page.

Latest updates to the Pembrolizumab + Gemcitabine in UC Subjects Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedA site-wide NIH announcement about the transition from “Artificial Intelligence” to “Super Intelligence” and related updates is no longer displayed.SummaryDifference1%

- Check20 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check27 days agoChange DetectedA banner was added announcing NIH updates and FAQs about the transition from “Artificial Intelligence” to “Super Intelligence” terminology.SummaryDifference1%

- Check34 days agoChange DetectedThe ClinicalTrials.gov error page footer shows a newer site revision number.SummaryDifference0.2%

- Check41 days agoChange DetectedThe site footer’s revision identifier changed from v3.7.0 to v3.7.1, while the page still displays a 403 error.SummaryDifference0.2%

- Check62 days agoChange DetectedAccess to the study page NCT02365766 now returns a 403 Forbidden error, displaying a standard error page instead of the study content.SummaryDifference22%

Stay in the know with updates to Pembrolizumab + Gemcitabine in UC Subjects Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Gemcitabine in UC Subjects Clinical Trial page.